Revefenacin

Yupelri (revefenacin) is a small molecule pharmaceutical. Revefenacin was first approved as Yupelri on 2018-11-09. It is used to treat chronic obstructive pulmonary disease in the USA. It is known to target muscarinic acetylcholine receptor M2, muscarinic acetylcholine receptor M1, muscarinic acetylcholine receptor M4, muscarinic acetylcholine receptor M3, and muscarinic acetylcholine receptor M5. Yupelri's patents are valid until 2031-08-25 (FDA).